STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Immunicum har fått läkemedelskandidaten ilixadencel vid behandling av mjukdelssarkom (soft tissue
Ilixadencel har genomgående upprätthållit en positiv säkerhets- och tolerabilitetsprofil och visat initiala tecken på effekt, som visats i den randomiserade Fas II-studien MERECA. Ilixadencel är på väg mot klinisk utveckling i sen fas.
Of 17 HCC patients enrolled, 12 patients received ilixadencel at the dose of 10 × 106 cells (six as monotherapy and six in combination with sorafenib), and five received ilixadencel at the dose of 20 × 106 cells as monotherapy. The primary objective was to evaluate tolerability. Ilixadencel is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy The active ingredients of ilixadencel are dendritic cells (DC) derived from healthy blood donors.
Nature-artikeln idag - stöd för ilixadencel : I abstractet förklaras att framgång i behandlingen med checkpointhämmare kräver optimalt primade CD8+ T-celler inn. Intratumoral administration of an immune primer is a therapeutic vaccine strategy aimed to trigger dendritic cell (DC)-mediated cross-presentation of cell-associated tumor antigens to cytotoxic CD8 + T cells without the need for tumor antigen characterization. Ilixadencel Targeting solid tumors with an off-the-shelf, cell-based immune primer Immunicum’s clinical program ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. Phase I Trial Evaluating Safety and Efficacy of Intratumorally Administered Inflammatory Allogeneic Dendritic Cells (Ilixadencel) in Advanced Gastrointestinal Stromal Tumors Phase I Trial Evaluating Safety and Efficacy of Intratumorally Administered Inflammatory Allogeneic Dendritic Cells (Ilixadencel) in Advanced Gastrointestinal Stromal Tumors Ilixadencel is an immune primer designed to increase the body’s defenses against cancer cells. It uses immune cells called dendritic cells, which play a key role in the activation of T-cells, another immune subset with the ability to fight cancers. The dendritic cells are collected from healthy donors. Ilixadencel is an investigational anti-cancer vaccine that uses dendritic cells, a type of immune cell, to instruct T-cells to attack and destroy cancer cells.
Ilixadencel. Targeting solid tumors with an off-the-shelf, cell-based immune primer. Immunicum’s clinical program ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By administration through intratumoral injection, these cells
2020-02-10 Any prior treatment with ilixadencel or prior treatment with anticancer agents (except pembrolizumab or other CPI for subjects in Phase 1b) within 4 weeks of starting study medication. Major surgery or significant traumatic injury within 4 weeks before study start.
we assessed ilixadencel as a single agent and combined with sorafenib in advanced HCC. Of 17 HCC patients enrolled, 12 patients received ilixadencel at the dose of 10 × 106 cells (six as monotherapy and six in combination with sorafenib), and five received ilixadencel at the dose of 20 × 106 cells as monotherapy.
Ilixadencel Targeting solid tumors with an off-the-shelf, cell-based immune primer Immunicum’s clinical program ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors.
10 Sep 2019 Ilixadencel is an off-the-shelf cancer immune primer developed for the treatment of solid tumors. The MERECA clinical trial evaluated the
22. Feb. 21. News Release. Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer · 18.
Att skriva referat exempel
Här visas generell information om substansen. Rekommenderat svenskt namn. ilixadencel (INN).
“We are very excited to have received the RMAT designation for ilixadencel in kidney cancer as it recognizes both the potential of our novel therapeutic
2017-06-23
2021-03-03
Adding the off-the-shelf, cell-based immunotherapy ilixadencel to frontline sunitinib was associated with an overall survival benefit in patients with metastatic renal cell carcinoma. Ilixadencel showed strong clinical activity with a potential overall survival (OS) benefit in patients with newly diagnosed metastatic renal cell carcinoma (RCC),
January 26, 2021 - The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma.
Blogg mama nu
vd rollbeskrivning
kildehenvisning av bok
www braun com nordic
vad menas med en psykosomatisk modell
lisbeth salander movies in order
civilutredare polisen jobb
The FDA has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to ilixadencel, as treatment of metastatic renal cell carcinoma (RCC), Immunicum AB announced in a press release. 1. “We are very excited to have received the RMAT designation for ilixadencel in kidney cancer as it recognizes both the potential of our novel therapeutic
The trial evaluated the efficacy and safety of ilixadencel combined with the targeted anticancer drug Sutent (common name: sunitinib, sunitinib; developed by Pfizer) in the first-line treatment of patients with newly diagnosed metastatic renal cell carcinoma (mRCC). The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib (Sutent) trended toward a benefit in overall survival (OS) compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma (RCC).